Medicine and Dentistry
Ovarian Cancer
100%
Niraparib
98%
Progression Free Survival
67%
Homologous Recombination
47%
Cytoreductive Surgery
38%
Maintenance Therapy
33%
Placebo
31%
Debulking Surgery
21%
Post-Hoc Analysis
21%
Overall Survival
19%
Hazard Ratio
19%
BRCA Mutation
18%
Minimal Residual Disease
18%
First-Line Chemotherapy
18%
Neoplasm
18%
Diseases
18%
Subgroup Analysis
16%
Cancer Recurrence
16%
Embolization
16%
Olaparib
16%
Arteriovenous Malformation
16%
Monotherapy
16%
Vaginal Delivery
16%
Enbucrilate
16%
Ovary Metastasis
16%
Polycystic Ovary Syndrome
16%
Meta-Analysis
16%
Glycon
16%
Metastatic Colon Cancer
16%
Clomifene
16%
Target Lesion
14%
BRCA2
13%
Adverse Event
13%
Recurrent Disease
12%
Neoadjuvant Chemotherapy
10%
Ovulation
10%
Progressive Disease
10%
Metastatic Carcinoma
9%
Gynecology
9%
Obstetrics
9%
Thrombocytopenia
9%
BRCA1
8%
Disease Exacerbation
7%
Quality of Life
7%
Odds Ratio
6%
Numbers Needed to Treat
6%
Anemia
6%
Vagina Bleeding
5%
Cancer Staging
5%
Hysterectomy
5%
Keyphrases
Niraparib
49%
Advanced Ovarian Cancer
37%
Progression-free Survival
35%
PRIMA
32%
ENGOT
32%
Homologous Recombination Deficiency
27%
Placebo
24%
Newly Diagnosed
22%
Confidence Interval
20%
BRCA mutation
18%
Platinum-based Chemotherapy
17%
Uterine Arteriovenous Malformation
16%
Successful Pregnancy
16%
Maintenance Treatment
16%
Vaginal Delivery
16%
Cyanoacrylate Embolization
16%
Olaparib
16%
Platinum-resistant Ovarian Cancer
16%
Newly Diagnosed Ovarian Cancer
16%
N-butyl Cyanoacrylate
16%
Ovarian Involvement
16%
Ovarian Metastasis
16%
Colorectal Adenocarcinoma
16%
Polycystic Ovary Syndrome
16%
Meta-analysis
16%
Metformin
16%
Colon Cancer
16%
Cytoreductive Surgery
16%
Hazard Ratio
15%
Median Progression-free Survival
12%
Optimal Cytoreduction
12%
Median Overall Survival
12%
Starting Dose
11%
Ovulation
11%
Clomiphene
11%
Tumor
11%
Overall Survival
10%
Treatment-related Adverse Events
10%
BRCA2
9%
Age Subgroups
9%
Thrombocytopenia
9%
Suboptimal Cytoreduction
8%
Metastasis
8%
Health-related Quality of Life
7%
Odds Ratio
7%
Number-needed-to-treat
7%
Clomiphene Citrate Resistance
7%
First-line Maintenance Therapy
7%
Anemia
6%
Traditional Therapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Niraparib
98%
Ovary Cancer
84%
Progression Free Survival
57%
Chemotherapy
37%
Placebo
28%
Diseases
21%
Minimal Residual Disease
18%
First-Line Chemotherapy
18%
Monotherapy
16%
Cancer Recurrence
16%
Neoplasm
11%
Adverse Event
11%
Recurrent Disease
10%
Thrombocytopenia
9%
Overall Survival
6%
Disease Exacerbation
6%
